



**COLORADO**

**Department of Health Care  
Policy & Financing**

## **P&T COMMITTEE MEETING**

**Agenda January 12, 2021**

**1:00 p.m. – 5:00 p.m.**

**Zoom Webinar – Registration Link**

[https://magellanhealth.zoom.us/webinar/register/WN\\_djrylmPdQLCujiUzy3QA1w](https://magellanhealth.zoom.us/webinar/register/WN_djrylmPdQLCujiUzy3QA1w)

### **Committee Member Introductions**

- Chief Medical Officer Introduction
- Openings/New Appointments
- Vote on New Chair/Vice Chair

### **Unfinished Business and General Orders**

- Approval of minutes from October 06, 2020 P&T meeting
- Update on Non-Steroidal Anti-Inflammatories (NSAIDs), Oral
- Update on Non-Steroidal Anti-Inflammatories (NSAIDs), Non-Oral
- Update on Antibiotics, Inhaled
- Update on Hepatitis C Virus Treatments - Direct-Acting Antivirals (DAAs)
- Update on Pulmonary Arterial Hypertension (PAH) Agents
  - Phosphodiesterase Inhibitors (PDEIs)
  - Endothelial Antagonists
  - Prostanoids
  - Guanylate Cyclase Stimulators
- Update on Triptans and other Migraine Treatments, Oral & Non-Oral
- Update on Antipsoriatics, Oral
- Update on Antipsoriatics, Topical
- Update on Antiemetics
- Update on H. Pylori Treatments
- Update on Methotrexate Products
- Update on Targeted Immune Modulators (TIMs)
- Update on Antihyperuricemics
- Update on Mass review drug classes\*:
  - Antiherpetic Agents, Oral and Topical
  - Fluoroquinolones, Oral
  - Hepatitis C Virus Treatments – Ribavirin Products

- Newer Generation Antidepressants
- Monoamine Oxidase Inhibitors (MAOIs)
- Tricyclic Antidepressants (TCAs)
- Pancreatic Enzymes
- Proton Pump Inhibitors
- Non-Biologic Ulcerative Colitis Agents, Oral & Rectal
- Antiplatelet Agents
- Epinephrine (self-administered) Products

### **New Business**

- Updates from the Prior Authorization Call Center

### **Drug Classes Up for Review:**

- Review of Diabetes Management – Insulins
- Review of Glucagon, Self-Administered – *removed from Mass Review*
- Review of Lipotropics
- Review of Cardiovascular Agents
  - Alpha-Blockers
  - Beta-Blockers & Combinations
  - Calcium Channel Blockers
- Review of Leukotriene Modifiers
- Review of Multiple Sclerosis Agents
- Review of Anti-Parkinson's Agents
  - Dopa Decarboxylase Inhibitors & Combinations
  - MAO-Bs
  - Dopamine Agonists
  - Other
- Review of Antimigraine Agents – Calcitonin Gene-Related Peptide (CGRP) Inhibitors
- Review of Atypical Antipsychotics
- Review of Sedative Hypnotics
  - Non-Benzodiazepine
  - Benzodiazepine
- Review of Anxiolytics
- Review of Anorectal, Hemorrhoidal, and Other Topical Anesthetic Agents
- Review of Ophthalmics, Anti-Inflammatory
- Review of Ophthalmics, Glaucoma Agents
- **Mass review drug classes\***:
  - Statins & Statin Combinations
  - Lithium Agents
  - Neurocognitive Disorder Agents
  - Topical Steroids
    - Low Potency
    - Medium Potency

- High Potency
- Very High Potency
- Growth Hormones
- Bile Salts
- Immune Globulins
- Intranasal Rhinitis Agents
- Ophthalmic Allergy Agents

**Each Review will contain:**

- Oral presentation by manufacturers, providers, and public
- Overview for each Drug Class, including market share and FDA updates
- Committee Discussion and Recommendations for each Class

\*Mass review drug classes will only include:

Overview for each Drug Class, including market share and FDA updates

**Upcoming Meeting Date:** Tuesday, April 13, 2021; 1:00 p.m. – 5:00 p.m.

**Presentations:**

Interested parties who want to present at the meeting shall give advanced notice, no later than January 5, 2021 at 5pm MT, and provide a one-page summary of the clinical information that will be presented for P&T Committee dissemination.

Please contact Brittany Schock, PDL Pharmacist, at 303-866-6371 or by email, [brittany.schock@state.co.us](mailto:brittany.schock@state.co.us) and carbon copy Jessica Czechowski, Pharmacist Account Executive, [jlczechowski@magellanhealth.com](mailto:jlczechowski@magellanhealth.com) to give advance notice to present at the meeting and submit written public comments for approval. Once approved, summaries will be distributed to all P&T Committee Members. Refer to the Policies and Procedures document for requirements of Stakeholder comments.

<https://www.colorado.gov/pacific/sites/default/files/PT%20committee%20Policy%20Oct%202020.pdf>